Management of Elevated Liver Enzymes in Patients Receiving Isotretinoin

Grading of Transaminitis

• Grade 2 elevation is defined as AST or ALT 3–5 × the upper limit of normal (ULN). 1
• Grade 3 elevation is defined as AST or ALT 5–20 × the ULN. 1
• Grade 4 elevation is defined as AST or ALT > 20 × the ULN. 1

Treatment Decisions Based on Grade

• Grade 2–3 elevations: Temporarily discontinue isotretinoin and perform weekly liver‑enzyme monitoring until values fall to Grade 1 or lower. 1
• Grade 4 elevation: Permanently discontinue isotretinoin and arrange immediate referral to hepatology. 1
• Grade 4 elevation: Consider liver biopsy when the injury is steroid‑refractory or when an alternative diagnosis would change management. 1

Recommendations for Concomitant Medications and Supplements

• Patients should stop all non‑essential medications and any known hepatotoxic agents, including dietary supplements such as protein powders, creatine, and herbal extracts. 1

Monitoring Frequency for High‑Risk Patients

• Presence of concurrent hepatotoxic medications warrants more frequent LFT monitoring (every 2–4 weeks initially). 1
• Obesity or diabetes increases the risk of hypertriglyceridemia and fatty liver, justifying closer surveillance. 2

Epidemiology and Guideline Context (American Academy of Dermatology)

• Abnormal liver‑function tests occur in 0.8 %–10.4 % of patients treated with isotretinoin, but only 0.9 %–4.7 % require drug discontinuation. The 2024 AAD guideline emphasizes that most elevations are mild and self‑limited. 3

Lipid Monitoring Parallel to LFTs

• Triglyceride abnormalities are observed in 7.1 %–39 % of isotretinoin patients, a substantially higher incidence than clinically significant LFT elevations, underscoring the need for routine lipid assessment. 3

Liver Enzyme Monitoring for Oral Isotretinoin

Recommended Monitoring Schedule

• The American Academy of Dermatology recommends checking liver enzymes at baseline and at 2 months into treatment, with additional monitoring only as clinically indicated or with dose changes 4
• Baseline testing should include obtaining ALT and AST before starting isotretinoin, and a single follow-up at 2 months to recheck liver enzymes once treatment dose is established 4

Management of Elevated Liver Enzymes

• For Grade 2-3 elevations, the British Association of Dermatologists recommends discontinuing isotretinoin temporarily if transaminases exceed 3 times upper normal limit, instituting weekly monitoring until levels normalize, and referring to gastroenterology if bilirubin is elevated or ALT is high 5, 6, 7
• Permanent discontinuation of isotretinoin may be necessary for persistent severe elevations 5, 6, 7

Special Populations Requiring More Frequent Monitoring

• Patients with pre-existing liver disease, concurrent hepatotoxic medications, history of excess alcohol intake, or dose adjustments or changes require more frequent monitoring, every 2-4 weeks initially, then every 3 months 5, 6, 7, 4

Common Pitfalls to Avoid

• The American Academy of Dermatology guidelines explicitly state that routine monitoring is unwarranted in low-risk patients, and the same conservative approach applies to liver enzymes 4
• While liver enzymes require minimal monitoring, triglycerides should be checked at baseline and 2 months, as severe hypertriglyceridemia poses acute pancreatitis risk 5, 6, 7